CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer
- 8 October 2024
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (37) , 2915-2925
Abstract
Asparagine synthetase (ASNS) catalyzes the biosynthesis of asparagine from aspartate and glutamine. Cells lacking ASNS, however, are auxotrophic for asparagine. Use of L-asparaginase to promote asparagine starvation in solid tumors with low ASNS levels, such as pancreatic ductal adenocarcinoma (PDAC), is a rationale treatment strategy. However, tumor cell resistance to L-asparaginase has limited its clinical utility. Our preclinical studies show that RAS/MAPK signaling circumvents L-asparaginase-induced tumor killing, but L-asparaginase and MEK inhibition potentiated tumor killing; suggesting that this combination may provide meaningful clinical benefit to patients with PDAC. This Phase I trial (NCT05034627) will evaluate the safety and tolerability of the MEK inhibitor, cobimetinib, in combination with pegylated L-asparaginase, L calaspargase pegol-mknl, in patients with locally-advanced or metastatic PDAC.Keywords
Funding Information
- Center for Strategic Scientific Initiatives, National Cancer Institute (R35CA197465)
- Genentech
- Servier
This publication has 58 references indexed in Scilit:
- The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell ResolutionCell, 2020
- High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers2020
- Cyclic Multiplexed-Immunofluorescence (cmIF), a Highly Multiplexed Method for Single-Cell Analysis2019
- As Extracellular Glutamine Levels Decline, Asparagine Becomes an Essential Amino AcidCell Metabolism, 2018
- Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via ATF4 and Alters Sensitivity to L-AsparaginaseCancer Cell, 2018
- A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumorsInvestigational New Drugs, 2016
- Hallmarks of Cancer: The Next GenerationCell, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2000